NCT06432647View on ClinicalTrials.gov

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

November 25, 2024

Study Completion Date

November 25, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

ATH-1105

ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.

DRUG

Placebo

Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.

Trial Locations (1)

75247

Fortrea Clinical Research Unit Inc., Dallas

Sponsors

Lead Sponsor

Athira Pharma
All Listed Sponsors
collaborator

Fortrea Holdings, Inc.

UNKNOWN

lead

Athira Pharma

INDUSTRY

NCT06432647 - A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 | Biotech Hunter | Biotech Hunter